This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.03.070v1 48/9/1800    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iribarren, C. Articles by Fortmann, S. P. Search for Related Content PubMed PubMed Citation Articles by Iribarren, C. Articles by Fortmann, S. P.

CLINICAL RESEARCH: METABOLIC SYNDROME

Metabolic Syndrome and Early-Onset Coronary Artery Disease

Is the Whole Greater Than Its Parts?

Carlos Iribarren, MD, MPH, PhD^_*,,_*, Alan S. Go, MD^_*,, Gail Husson, MPH, Med^_*, Stephen Sidney, MD, MPH^_*, Joan M. Fair, ANP, PhD, Thomas Quertermous, MD, Mark A. Hlatky, MD^,|| and Stephen P. Fortmann, MD

^_* Kaiser Permanente Division of Research, Oakland, California
Departments of Epidemiology, Biostatistics, and Medicine, University of California, San Francisco, California
Stanford Prevention Research Center
Division of Cardiovascular Medicine
^|| Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California

Manuscript received December 19, 2005; revised manuscript received February 10, 2006, accepted March 16, 2006.

^_* Reprint requests and correspondence: Dr. Carlos Iribarren, Research Scientist, Kaiser Permanente, Division of Research, 2000 Broadway, Oakland, California 94612. (Email: cgi{at}dor.kaiser.org).

OBJECTIVES: We sought to examine the association between the metabolic syndrome (MetS) (defined both by the 2001 National Cholesterol Educational Program Adult Treatment Panel III [ATP-III] definition and the American Heart Association/National Heart, Lung and Blood Institute [AHA/NHLBI] revision incorporating the lower threshold for impaired fasting glucose [IFG]) and early-onset coronary artery disease (CAD).

BACKGROUND: The impact of MetS on premature CAD has not been studied extensively. Lowering the threshold to define the IFG component (from 110 to 100 mg/dl) and the value of the syndrome as a whole versus its individual components are subjects of intense debate.

METHODS: We performed a case-control study with 393 early-onset CAD subjects (acute myocardial infarction, angina with 50% stenosis, or coronary revascularization) in men under age 46 years or women under age 56 years and 393 control subjects individually matched for gender, age, and race/ethnicity.

RESULTS: By conditional logistic regression, presence of ATP-III MetS without diabetes (adjusted odds ratio [adj-OR] 4.9; 95% confidence interval [CI] 3.4 to 8.0) and with diabetes (adj-OR 8.0, 95% CI 4.39 to 14.6) was a strong independent determinant of early-onset CAD. Using the AHA/NHLBI revision, these ORs became slightly stronger. However, neither definition of MetS remained significantly associated with early-onset CAD in multivariate models adjusting for individual components.

CONCLUSIONS: The presence of MetS imparts a high risk of early-onset clinical CAD, but the prognostic information associated with the syndrome is not greater than the sum of its parts.

Abbreviations and Acronyms   ADA = American Diabetes Association   ADVANCE = Atherosclerotic Disease, Vascular Function, and Genetic Epidemiology   AHA/NHLBI = American Heart Association/National Heart, Lung, and Blood Institute   CAD = coronary artery disease   CARDIA = Coronary Artery Risk Development in Young Adults   HOMA-IR = homeostasis model assessment of insulin resistance   IFG = impaired fasting glucose   KPNC = Kaiser Permanente of Northern California   MetS = metabolic syndrome   NCEP-ATP-III = National Cholesterol Educational Program Adult Treatment Panel III

This article has been cited by other articles:

				J. S. Lee, S.-I. Cho, and H. S. Park Metabolic syndrome and cancer-related mortality among Korean men and women Ann. Onc., September 16, 2009; (2009) mdp344v1. [Abstract] [Full Text] [PDF]

				T. L. Assimes, J. W. Knowles, A. Basu, C. Iribarren, A. Southwick, H. Tang, D. Absher, J. Li, J. M. Fair, G. D. Rubin, et al. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study Hum. Mol. Genet., August 1, 2008; 17(15): 2320 - 2328. [Abstract] [Full Text] [PDF]

				J. R. Burt, C. Iribarren, J. M. Fair, L. C. Norton, M. Mahbouba, G. D. Rubin, M. A. Hlatky, A. S. Go, S. P. Fortmann, and for the Atherosclerotic Disease, Vascular Function Incidental Findings on Cardiac Multidetector Row Computed Tomography Among Healthy Older Adults: Prevalence and Clinical Correlates Arch Intern Med, April 14, 2008; 168(7): 756 - 761. [Abstract] [Full Text] [PDF]

				D. Ardigo, T. L. Assimes, S. P. Fortmann, A. S. Go, M. Hlatky, E. Hytopoulos, C. Iribarren, P. S. Tsao, R. Tabibiazar, T. Quertermous, et al. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease Physiol Genomics, November 14, 2007; 31(3): 402 - 409. [Abstract] [Full Text] [PDF]

				S. Inchiostro, G. P. Fadini, S. V. de Kreutzenberg, N. Citroni, and A. Avogaro Is the Metabolic Syndrome a Cardiovascular Risk Factor Beyond Its Specific Components? J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2465 - 2465. [Full Text] [PDF]

				J. Wang, S. Ruotsalainen, L. Moilanen, P. Lepisto, M. Laakso, and J. Kuusisto The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns Eur. Heart J., April 1, 2007; 28(7): 857 - 864. [Abstract] [Full Text] [PDF]